User:Mr. Ibrahem/Avalglucosidase alfa

Avalglucosidase alfa, sold under the brand name Nexviazyme, is a medication used to treat glycogen storage disease type II (Pompe disease). It is used in those over the age of one with late onset disease. It is given gradually into a vein every two weeks.

Common side effects include headache, tiredness, diarrhea, nausea, joint pain, dizziness, muscle pain, itchiness, shortness of breath, and skin redness. Other side effects may include anaphylaxis, infusion reaction, and cardiorespiratory failure. It is an enzyme replacement therapy, specifically to replace alpha-glucosidase. It is a hydrolytic lysosomal glycogen-specific enzyme.

Avalglucosidase alfa was approved for medical use in the United States in 2021 and Europe in 2022. It costs about 900 USD per 50-mg in the United States as of 2021. In Canada it costs about 525,000 CAD per person per year as of 2022.